Profund Advisors LLC Purchases 3,105 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Profund Advisors LLC boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 22.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,919 shares of the biopharmaceutical company’s stock after acquiring an additional 3,105 shares during the quarter. Profund Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $4,175,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in ALNY. Wellington Management Group LLP raised its stake in shares of Alnylam Pharmaceuticals by 9.0% in the second quarter. Wellington Management Group LLP now owns 2,110,407 shares of the biopharmaceutical company’s stock worth $635,296,000 after purchasing an additional 174,482 shares during the last quarter. Legal & General Group Plc bought a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at about $278,321,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 7.4% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 727,848 shares of the biopharmaceutical company’s stock valued at $219,104,000 after acquiring an additional 50,329 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at about $148,128,000. Finally, Swiss National Bank boosted its holdings in shares of Alnylam Pharmaceuticals by 7.9% during the 1st quarter. Swiss National Bank now owns 387,720 shares of the biopharmaceutical company’s stock valued at $128,285,000 after acquiring an additional 28,520 shares during the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Quarterly results exceeded expectations. Alnylam reported $16.26 in adjusted earnings per share versus the $1.66 consensus estimate, while revenue rose 16.7% year over year to $1.46 billion, slightly above forecasts. The company maintained its fiscal 2026 product-sales outlook and expects $4.2 billion–$4.5 billion in 2026 TTR sales. Alnylam Q3 earnings beat
• Positive Sentiment: Several analysts still see substantial long-term upside. Chardan Capital, TD Cowen, Goldman Sachs and RBC retained positive ratings, although they reduced their price targets. Their revised targets remain well above the current trading level. Chardan Capital rating
• Neutral Sentiment: Pipeline investment could support future growth but increases execution risk. Alnylam expanded the TRITON-CM nucresiran heart-disease study to approximately 2,250 patients while maintaining an anticipated launch around 2030. Management described its conviction in the program as high, but the longer timeline limits near-term revenue benefits. Alnylam TTR sales and trial update
• Negative Sentiment: Demand-growth concerns overshadowed the earnings beat. Slower Amvuttra patient starts and moderating U.S. Amvuttra and Onpattro sales growth raised concerns that the company’s core TTR business may be losing momentum. Management also acknowledged that it needs to improve execution, adding to uncertainty around the franchise. ALNY demand growth concerns
• Negative Sentiment: Analyst sentiment became more cautious. Bernstein downgraded ALNY to “market perform,” while Stifel cut its rating to “hold.” Multiple firms lowered price targets, including Bernstein from $376 to $199 and Goldman Sachs from $536 to $320, reflecting increased valuation and policy risks.

Insider Activity

In other news, EVP Bryan Supran sold 1,758 shares of the company’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the sale, the executive vice president directly owned 12,807 shares in the company, valued at $2,905,652.16. This represents a 12.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY opened at $165.00 on Friday. The firm has a 50 day moving average of $236.49 and a 200 day moving average of $286.19. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75. The firm has a market capitalization of $22.08 billion, a price-to-earnings ratio of 8.57 and a beta of 0.28. Alnylam Pharmaceuticals, Inc. has a 12-month low of $163.30 and a 12-month high of $479.79.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 EPS for the quarter, beating analysts’ consensus estimates of $1.66 by $14.60. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 246.94%. The business had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.43 billion. During the same period in the prior year, the company earned $2.90 earnings per share. The firm’s revenue was up 16.7% on a year-over-year basis. On average, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.58 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on ALNY. UBS Group reissued a “buy” rating and set a $329.00 price objective (down from $550.00) on shares of Alnylam Pharmaceuticals in a report on Friday. HC Wainwright restated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday. Morgan Stanley cut their target price on shares of Alnylam Pharmaceuticals from $300.00 to $240.00 and set an “equal weight” rating for the company in a research report on Friday. Zacks Research lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 23rd. Finally, Citigroup lowered their price target on Alnylam Pharmaceuticals from $340.00 to $320.00 and set a “buy” rating on the stock in a report on Wednesday, October 14th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $317.95.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.